FindTrial
Sign In

PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare

PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07209722
Enrollment
1377
Registered
2025-10-07
Start date
2023-09-22
Completion date
2025-08-16
Last updated
2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PrEP Precriptions for Reproductive Aged Women

Brief summary

The purpose of the study is to learn more about health care providers' experiences and perspectives on prescribing HIV pre-exposure prophylaxis, also known as PrEP. Providers and patients in gynecology clinics were interviewed and completed surveys to measure the feasibility and preference of prescribing PrEP.

Interventions

BEHAVIORALPrEP acronym (pre-exposure prophylaxis)

Tracked PrEP prescriptions over 8 months among patients who completed the survey

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Patient of UAB GYN clinic

Exclusion criteria

* Not a patient of UAB GYN clinic

Design outcomes

Primary

MeasureTime frameDescription
PrEP Prescriptions8 monthsNumber of participants receiving a new PrEP prescription during the recruitment period

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichael Mugavero, MD

University of Alabama at Birmingham

Baseline characteristics

Characteristic—
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
1377 Participants
Age, Continuous35 year
STANDARD_DEVIATION 11.5
Race/Ethnicity, Customized
Asian
30 Participants
Race/Ethnicity, Customized
Black
100 Participants
Race/Ethnicity, Customized
Hispanic
2 Participants
Race/Ethnicity, Customized
White
375 Participants
Region of Enrollment
United States
242 Participants
Sex: Female, Male
Female
1135 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1,1350 / 242
other
Total, other adverse events
0 / 1,1350 / 242
serious
Total, serious adverse events
0 / 1,1350 / 242

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026